ENANTA PHARMACEUTICALS, INC (ENTA) Overview
- 1 Apr 2026: Period ending 30 Jun 2026; Estimate (m); Actual -0.67; Beat / miss (m).
- 1 Jan 2026: Period ending 31 Mar 2026; Estimate (m); Actual -0.45; Beat / miss (m).
- 1 Oct 2025: Period ending 31 Dec 2025; Estimate (m); Actual -0.42; Beat / miss (m).
- 1 Apr 2025: Period ending 30 Jun 2025; Estimate (m); Actual -0.85; Beat / miss (m).
Stock Price Chart
View more →Blue: Split-adjusted close · Orange: Cumulative dividend-reinvested close
Logarithmic scale. Both lines share the same starting value for the selected range.
- Last close
- $11.00
- Previous close
- $12.64
- Change
- -$1.64
- Change (%)
- -12.97%
- Close date
- 2026-11-06
- Previous close date
- 2026-09-29
- Open
- (m)
- Day high
- (m)
- Day low
- (m)
- Last session volume
- (m)
- Last session value
- (m)
- Currency
- USD
- Price basis
- split-adjusted
- Volume basis
- (m)
Performance
View more →Cumulative total returns · 2026-09-29
YTD
- ENTA
- -19.85%
- S&P 500
- (m)
1 year
- ENTA
- -16.62%
- S&P 500
- (m)
3 years
- ENTA
- +13.16%
- S&P 500
- (m)
5 years
- ENTA
- -77.47%
- S&P 500
- (m)
Earnings trends
View more →Earnings per share
USD / share · As filed
30 Jun 2026 ○ Estimate (m) ● Actual -0.67
Comparison details
| Period start | Period ending | Estimate | Actual | Beat / miss | Report date |
|---|---|---|---|---|---|
| 1 Apr 2026 | 30 Jun 2026 | (m) | -0.67 | (m) | (m) |
| 1 Jan 2026 | 31 Mar 2026 | (m) | -0.45 | (m) | (m) |
| 1 Oct 2025 | 31 Dec 2025 | (m) | -0.42 | (m) | (m) |
| 1 Apr 2025 | 30 Jun 2025 | (m) | -0.85 | (m) | (m) |
| 1 Jan 2025 | 31 Mar 2025 | (m) | -1.06 | (m) | (m) |
30 Sept 2025 ○ Estimate (m) ● Actual -3.84
Comparison details
| Period start | Period ending | Estimate | Actual | Beat / miss | Report date |
|---|---|---|---|---|---|
| 1 Oct 2024 | 30 Sept 2025 | (m) | -3.84 | (m) | (m) |
| 1 Oct 2023 | 30 Sept 2024 | (m) | -5.48 | (m) | (m) |
| 1 Oct 2022 | 30 Sept 2023 | (m) | -6.38 | (m) | (m) |
| 1 Oct 2021 | 30 Sept 2022 | (m) | -5.91 | (m) | (m) |
| 1 Oct 2020 | 30 Sept 2021 | (m) | -3.92 | (m) | (m) |
(m)
Revenue vs. Earnings
USD
30 Jun 2026 ■ Revenue 14.36M ■ Earnings -19.50M — Profit margin -135.81%
30 Sept 2025 ■ Revenue 65.32M ■ Earnings -81.89M — Profit margin -125.36%
Analyst insights
View more →| Ratings | Buy | Hold | Sell | Other ratings | Last Close | Average Target | Upside | High Target | Low Target |
|---|---|---|---|---|---|---|---|---|---|
| (m) | (m) | (m) | (m) | (m) | $11.00 | (m) | (m) | (m) | (m) |
Recent news
View more →(m)
YouTube videos mentioning ENTA
View more →(m)
Statistics
View more →Retained observations as of 2026-11-13; financial period ending 30 Jun 2026.
- Forward P/E
- (m)
- PEG ratio · 5-year expected
- (m)
- Shares held by insiders
- (m)
- Insider transactions · change (%)
- (m)
- Shares held by institutions
- (m)
- Institutional transactions · change (%)
- (m)
- Diluted EPS · 12 month
- (m)
- EPS estimate · next quarter
- (m)
- EPS estimate · next year
- (m)
- EPS growth · current annual estimate
- (m)
- EPS growth · next annual estimate
- (m)
- EPS growth · next 5 years expected
- (m)
- EPS growth · past 3 years annualized
- (m)
- EPS growth · past 5 years annualized
- (m)
- EPS change · 12 months vs prior year
- (m)
- EPS change · latest quarter vs previous quarter
- (m)
- Latest earnings report date
- (m)
- EPS surprise · latest reported quarter
- (m)
- Net income · 12 month
- $-63.23M
- Operating margin · 12 months
- -89.99%
- Profit margin
- -96.89%
- Return on assets · 12 month
- -21.15%
- Named executive and board stock awards · latest fiscal year
- (m)
- Index membership
- (m)
- Employees
- 120.00
- IPO date
- (m)
- Options available
- (m)
- Shortable
- (m)
- Analyst recommendation
- (m)
- Analyst target price
- (m)
- Price volatility · week
- (m)
- Price volatility · month
- (m)
- Average true range · 14 sessions
- (m)
- Relative strength index · 14 sessions
- (m)
- Relative volume
- (m)
- Average daily volume
- 255.85K
- Latest session volume
- (m)
- Last session value
- (m)
- 30 days ago session value
- (m)
- 1 year ago session value
- (m)
- Number of trades
- (m)
- Total return · week
- 1.77%*
- Total return · month
- -7.06%*
- Total return · quarter
- -12.89%*
- Total return · half year
- 3.78%*
- Total return · year to date
- -19.85%*
- Total return · 1 year
- -16.62%*
- Total return · 3 years
- 13.16%*
- Total return · 5 years
- -77.47%*
- Market cap
- (m)
- Book value per share · latest quarter
- (m)
- Price / cash · latest quarter
- (m)
- Enterprise value
- (m)
- Enterprise value / revenue
- (m)
- Enterprise value / EBITDA
- (m)
- Dividend · 12 months per share
- (m)
- Dividend ex-date
- (m)
- Next dividend ex-date
- (m)
- Next dividend amount per share
- (m)
- Dividend growth · 3 years annualized
- (m)
- Dividend growth · 5 years annualized
- (m)
- R&D / revenue · 12 months
- 132.15%
- Revenue · 12 month
- $65.26M
- Revenue growth · past 3 years annualized
- (m)
- Revenue growth · past 5 years annualized
- (m)
- Revenue change · 12 months vs prior year
- (m)
- Revenue change · latest quarter vs previous quarter
- (m)
- Revenue surprise · latest reported quarter
- (m)
- Operating cash flow · 12 months
- $-35.32M
- Free cash flow · 12 months (USD)
- $-36.94M
- Levered free cash flow · 12 month
- (m)
- Debt / equity · latest quarter
- (m)
- Long-term debt / equity · latest quarter
- (m)
- Return on equity · 12 month
- (m)
- Return on invested capital · 12 months
- (m)
- Previous close
- (m)
- Latest closing price
- (m)
- Latest session change (%)
- (m)
- 52-week high
- (m)
- 52-week low
- (m)
- Price vs 20-session moving average
- (m)
- Price vs 50-session moving average
- (m)
- Price vs 200-session moving average
- (m)
- Float shares
- (m)
- Short float (%)
- (m)
- Short ratio (days to cover)
- (m)
- Short interest (shares)
- (m)
Five-year projected P/E and P/S repeat the preceding five-year EPS and revenue CAGR, holding current price and market cap constant. Hover a calculated row for its formula. Net assets = assets − debt − payables − deferred revenue − obligations due within 1 year − obligations due after 1 year.
Holders breakdown
View more →| Breakdown | Ownership |
|---|---|
| (m) | Shares held by all insiders |
| (m) | Shares held by institutions |
| (m) | Float held by institutions |
| (m) | Institutions holding shares |
Other holders
(m)
Insider holders
(m)
Top institutional holders
(m)
Top mutual fund holders
(m)
ENANTA PHARMACEUTICALS, INC Overview
View more →(m)
(m)
- SEC CIK
- 1177648
- Industry (SIC)
- 2834 Pharmaceutical Preparations
- Country of operation
- United States
- Business address
- 4 KINGSBURY AVENUE, WATERTOWN, Massachusetts, 02472, United States
- Fiscal year end
- 0930
- Phone
- 617 607 0800
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |